News

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
The Pharma Letter19h
AstraZeneca in talks with Summit for over $15 billion license deal
UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...
The Manila Times on MSN13h
AstraZeneca eyes licensing lung cancer drug
ASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...
Stocks fade as tariff deadline looms large
London’s FTSE 100 ended flat as tariff worries kept enthusiasm to a minimum on Friday, while the pound edged slightly lower ...